Briacell, MSK to work on Bria-OTS+ clinical development

Dr. William Williams reports BRIACELL ANNOUNCES COLLABORATION WITH MSK ACCELERATOR TO ADVANCE BRIA-OTS+ FOR BREAST CANCER Briacell Therapeutics Corp. has arranged a collaboration with Memorial Sloan Kettering Cancer Center's (MSK) therapeutics accelerator cohort program to accelerate the clinical development of Bria-OTS+, Briacell's next-generation personalized off-the-shelf immunotherapy, for multiple cancer indications, including metastatic breast cancer, prostate cancer and other cancers. The collaboration starts with manufacturing, IND (investigational new drug) development and clinical protocol support for a phase 1 clinical trial with Bria-BRES+, Briacell's next-generation personalized immunotherapy for patients with breast cancer under the Bria-OTS+ platform. The partnership expands on Briacell's previously announced selection into MSK's accelerator program. As one of the world's foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education and discovery. Through the MSK therapeutics accelerator, MSK's therapeutic-based strategic collaboration program, Briacell will obtain access to MSK's clinical and institutional expertise, including cell therapy manufacturing, IND preparation, and submission and clinical development to expedite development of the Bria-OTS+ platform. "We are thrilled to collaborate with MSK's scientific and clinical experts to address the urgent unmet medical need of many thousands of metastatic breast cancer patients," stated Dr. William V. Williams, Briacell's president and chief executive officer. "We are honoured to be working with the team of cancer specialists at MSK," noted Dr. Miguel Lopez-Lago, PhD, Briacell's chief scientific officer. "This collaboration with MSK will accelerate the development of our advanced personalized off-the-shelf immunotherapy platform, Bria-OTS+, which we believe has the potential to transform cancer care and significantly improve patients' lives through its unique mechanism of action." "We look forward to working with Briacell through MSK's therapeutics accelerator to help advance this next-generation personalized immunotherapy into the clinic. Collaborations like this are essential to translating promising scientific innovations into potential new treatment options for patients," commented Dr. Shanu Modi, MD, breast medical oncologist and attending physician at MSK. About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. About MSK's therapeutics accelerator Through its therapeutics accelerator program, MSK partners with biotechnology companies to help advance innovative cancer therapeutics from early development through the clinic. By combining the resources of cutting-edge health care companies with MSK's world-renowned clinical and scientific expertise, the program fosters collaborations aimed at improving the treatment and management of cancer. MSK has institutional financial interests related to Briacell. We seek Safe Harbor.